| Name | Title | Contact Details |
|---|
At LumiThera, we are committed to developing solutions to prevent vision loss and blindness, improve visual function and stop or slow the progression of blinding diseases of the eye. We will continue to innovate non-invasive approaches to address unmet medical needs. LumiThera, Inc. is a commercial-stage medical device company initially focused on treating patients affected by dry age-related macular degeneration. The Company`s expertise is in the application of photobiomodulation (“PBM”), using non-invasive light emitting diodes (“LED”) for acute and chronic ocular diseases and disorders. The Company is developing an ophthalmic LED office-based instrument to be used in multiple ocular conditions or disorders as non-invasive medical treatments. Three clinical studies have demonstrated clinical and pathological benefits of PBM in treating subjects with dry AMD. The recent TORPA II clinical trial results demonstrating improvements in clinical outcomes of vision and reduction of pathological “drusen” following imaging analysis were published in December 2016 in ACTA Ophthalmologica, a top peer-reviewed Ophthalmology journal. The company recently completed the LIGHTSITE I clinical trial,a thirty subject dry AMD study partially supported by the National Eye Institute. The Valeda LIght Delivery System is now available for sale in the European Economic Area. The Valeda Light Delivery System is CE Marked. The device is not for sale in the USA.
Carter Dental Lab is a Stuttgart, AR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
PHS West Inc is a Hanover, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AEIOMED is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Proof, we believe that knowledge is power—and good health is a necessity. We`re a health technology and diagnostics company that is currently developing a cutting-edge, CRISPR-based platform for point-of-care facilities to test for COVID-19, with ambitions to transform in-home diagnostics across a broad spectrum of health applications in the future. Proof is the brainchild of Professor Feng Zhang, a world-renowned molecular biologist and leader of a research lab at the Broad Institute of MIT and Harvard. In early 2020, Dr. Zhang along with Dr. Jonathan Gootenberg and Dr. Omar Abudayyeh of the McGovern Institute pivoted their focus towards combating the emergent threat of the COVID-19 pandemic. Pioneers of the CRISPR gene-editing technology, the three scientists dropped everything to face the global public health crisis head on. Combining CRISPR and RT-LAMP technologies in a novel approach, our scientific team is developing a simple, streamlined molecular diagnostics platform that can quickly test for the presence of the SARS-CoV-2 virus. Intended for use within clinics, pharmacies, schools, workplaces and eventually homes, our easy-to-use, lab-quality test platform is undergoing rigorous R&D protocols so that we can provide fast, accurate diagnostics that will help communities take control of their health. We want to transform the anxiety of waiting days for COVID-19 test results into the peace of mind of quickly knowing what steps to take next. Our first test system, which we`re designing to detect SARS-CoV-2, will enable us to fulfill our mission of helping restore a degree of normalcy to our world. From there, we aim to transform personalized health, and expand our diagnostic platform to detect other diseases, with the goal of providing actionable health information that will allow people to lead better, healthier lives. If you`re with us, reach out today.